Development of 3D Multi-Parametric Ultrasound (MPUS) as a Decision Support Tool for Patients

Inclusion Criteria:

1. Participant is planned to undergo a new course of cancer therapy*.

2. Participant is age >/=18 years.

3. Participant has at least one target lesion (≥1cm and <14cm) amenable to imaging withultrasound

4. Participant is willing to comply with protocol requirements.

5. Participant has given written informed consent to participate in this study.

• Any line of cancer therapy is allowed, including systemic and localizedtreatments, after any prior treatment. For systemic combination treatments,prior treatment with either drug is allowed at the discretion of theinvestigators, including rechallenges with the same drug combination, forexample upon progression on imaging after a treatment break. For combinationtreatments where patients start treatment with different drugs at differenttimes, the start date of treatment is determined at the discretion of theinvestigators and can be the start date of the first drug or of the combinationtreatment. Repeat participation in the study is allowed, if patients areeligible again per their treatment plan

Exclusion Criteria:

1. Participant has documented anaphylactic or other severe reaction to any ultrasoundcontrast media or polyethylene glycol (PEG).

2. Participant has any comorbid condition** that, in the opinion of the treatingprovider or the Protocol Director, compromises the participant's ability toparticipate in the study.

• Examples: any mental condition that compromises the ability to follow a consentdiscussion, or to make informed decisions (except if represented by a LegallyAuthorized Representative [LAR]); any condition that makes the participant nota good candidate to have ultrasound exams with contrast agent.